On 30 April 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) announced it would limit the use of nasal decongestant sprays and drops containing xylometazoline and oxymetazoline to a maximum of five days. The change follows expert advice about side effects from prolonged use, including rebound congestion and rhinitis medicamentosa. New packaging and leaflets will state the five‑day limit and highlight the risks of overuse. Existing stock with a seven‑day claim may remain on sale, but patients are advised to follow the updated guidance. MHRA staff and pharmacists urge consumers to read patient information leaflets and to seek professional advice if symptoms persist beyond five days.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.